Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL

Manabu Muto, Professor at the Department of Therapeutic Oncology, Kyoto University’s Graduate School of Medicine Current rules make using Chugai Pharmaceutical’s multigene panel test FoundationOne CDx Cancer Genomic Profile as a companion diagnostic (CDx) difficult at medical institutions, a key...read more